Spearheading the Development of TCR-Based Approaches for Inhibition of RAS-Driven Cancers in Resistant Patient Populations
- Identifying and quantifying precise HLA-peptide targets for TCR-based therapies
- Novel specificity analysis of TCR to avoid off-target toxicities
- Focused clinical trial designs to integrate with existing standard of care for RAS-driven malignancies